Citations

Clear

2303 citation(s) found for "Yu, Edward".

The pericentriolar lattice of PtK2 cells exhibits temperature and calcium modulated behavior
Nemeth, Edward F. , Salisbury, Jeffrey L., Baron, Andre T. , Suman, Vera J.

Mayo Clinic

Journal of Cell Science | April 25, 2021 | Volume: 107 | Issue: 11 | Pages: 2993-3003

10.1242/jcs.107.11.2993 | PMID 7698999 Get It

ABSTRACT In this study, we demonstrate that manipulations of temperature and free calcium alter the morphology of the centrin-containing pericentriolar lattice of PtK2 cells. Immunofluorescence microscopy reveals that low-temperature incubation (4°C) causes anti-centrin-labeled pericentrosomal spots to coalesce in the peripheral cytoplasm, and fuses small spots into larger spots near the cell center. At electron microscopic resolution, well-formed pericentriolar satellites appear around the centrioles in response to incubation at 4°C. Elevated free calcium enhances these low-temperature-dependent effects. The data suggest that peri-centrosomal spots correspond to one or more pericentriolar satellites, and that pericentriolar satellites and centrosomal matrix are interconvertable forms of the same material. Transient elevation of intracellular free calcium at 37°C from a basal level of 3.7×10−8 M to a peak level of 2.0×10−7 M within 30 seconds with ionomycin results in a 35% increase in pericentrosomal spot number throughout the cytoplasm. The number of pericentrosomal spots is 50% larger 2 minutes after ionomycin addition; these spots are also nearer to the cell center as compared to 30 seconds after ionomycin addition. As intracellular free calcium returns to a basal level over 5 minutes, the number of spots and their cellular distribution resume a pretreatment value and pattern. We interpret these observations to indicate movement of pericentrosomal spots toward the cell center in response to the flux in intracellular free calcium. Alternatively, it is possible that no movement has occurred, but that the rise in free calcium has unmasked an epitope responsive to our anti-centrin antiserum. Regardless of the interpretation, we conclude that the pericentriolar lattice exhibits calcium-modulated behavior.
Efficacy and Safety of Tofacitinib Re-treatment for Ulcerative Colitis After Treatment Interruption: Results from the OCTAVE Clinical Trials
Panés, Julián , Vermeire, Séverine , Dubinsky, Marla C. , Loftus, Edward V. , Lawendy, Nervin, Wang, Wenjin , Salese, Leonardo , Su, Chinyu , Modesto, Irene , Colombel, J F. , Loftus, Edward V , Panes, Julian , Vermeire, Séverine , Guo, Xiang , Colombel, Jean‐Frédéric

Mayo Clinic

Journal of Crohn's and Colitis | April 22, 2021 | Volume: 15 | Issue: 11 | Pages: 1852-1863

10.1093/ecco-jcc/jjab065 | PMID 33884415 Get It

Abstract Background and Aims Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis. Here, we evaluate the efficacy and safety of tofacitinib re-treatment following treatment interruption in patients with ulcerative colitis. Methods Here, patients with clinical response to tofacitinib 10 mg b.d. induction therapy were randomised to receive placebo in OCTAVE Sustain. Those experiencing treatment failure after Week 8 of OCTAVE Sustain entered OCTAVE Open and re-initiated tofacitinib 10 mg b.d. [re-treatment subpopulation]; efficacy and safety data are presented up to Month 36 of OCTAVE Open. Results Median time to treatment failure following interruption was 169 (95% confidence interval [CI], 94.0–179.0) and 123 [95% CI, 91.0–168.0] days for induction remitters, and induction responders but non-remitters, respectively. Following re-treatment with tofacitinib, rates (non-responder imputation after a patient discontinued; latest observation carried forward imputation after a patient advanced to a subsequent study [NRI-LOCF]) of clinical response, remission, and endoscopic improvement were 74.0%, 39.0%, and 55.0% at Month 2, and 48.5%, 37.4%, and 42.4% at Month 36, respectively. Among induction remitters and induction responders but non-remitters, clinical response rates at Month 36 were 60.6% and 42.4% [NRI-LOCF], respectively. Efficacy was recaptured regardless of prior tumour necrosis factor inhibitor failure status. The safety profile of tofacitinib 10 mg b.d. re-treatment was consistent with the overall cohort and demonstrated no new safety risks associated with exposure of ≤36 months. Conclusions Median time to treatment failure was numerically higher in induction remitters versus induction responders but non-remitters. Following treatment interruption, efficacy was safely and successfully recaptured with tofacitinib 10 mg b.d. re-treatment in a substantial proportion of patients [ClinicalTrials.gov:NCT01458574;NCT01470612].
Role of α2-Adrenoceptor Subtypes in Suppression of L-Type Ca2+ Current in Mouse Cardiac Myocytes
Evdokimovskii, Edward V., Jeon, Ryoung‐Hoon , Park, Sungjo , Pimenov, Oleg Y. , Alekseev, Alexey E., Jeon, Ryounghoon

Mayo Clinic

International Journal of Molecular Sciences | April 16, 2021 | Volume: 22 | Issue: 8 | Pages: 4135

10.3390/ijms22084135 | PMID 33923625 Get It

Sarcolemmal α2 adrenoceptors (α2-AR), represented by α2A, α2B and α2C isoforms, can safeguard cardiac muscle under sympathoadrenergic surge by governing Ca2+ handling and contractility of cardiomyocytes. Cardiomyocyte-specific targeting of α2-AR would provide cardiac muscle-delimited stress control and enhance the efficacy of cardiac malfunction treatments. However, little is known about the specific contribution of the α2-AR subtypes in modulating cardiomyocyte functions. Herein, we analyzed the expression profile of α2A, α2B and α2C subtypes in mouse ventricle and conducted electrophysiological antagonist assay evaluating the contribution of these isoforms to the suppression of L-type Ca2+ current (ICaL). Patch-clamp electro-pharmacological studies revealed that the α2-agonist-induced suppression of ICaL involves mainly the α2C, to a lesser extent the α2B, and not the α2A isoforms. RT-qPCR evaluation revealed the presence of adra2b and adra2c (α2B and α2C isoform genes, respectively), but was unable to identify the expression of adra2a (α2A isoform gene) in the mouse left ventricle. Immunoblotting confirmed the presence only of the α2B and the α2C proteins in this tissue. The identified α2-AR isoform-linked regulation of ICaL in the mouse ventricle provides an important molecular substrate for the cardioprotective targeting.
A standard system phantom for magnetic resonance imaging
Stupic, Karl F. , Ainslie, Maureen, Boss, Michael A. , Charles, Cecil, Dienstfrey, Andrew , Evelhoch, Jeffrey L., Finn, Paul, Gimbutas, Zydrunas , Gunter, Jeffrey L. , Hill, David , Karaulanov, Todor , Liu, Guoying , Martin, Michele N. , Prasad, Pottumarthi V. , Rentz, Nikki S., Yuan, Chun , Keenan, Kathryn E , Yuan, Chun , Russek, Stephen E , Boss, Michael A , Jack, Clifford R. , Jackson, Edward F. , Keenan, Kathryn E. , Russek, Stephen E.

Mayo Clinic

Magnetic Resonance in Medicine | April 13, 2021 | Volume: 86 | Issue: 3 | Pages: 1194-1211

10.1002/mrm.28779 | PMID 33847012 Get It

Purpose A standard MRI system phantom has been designed and fabricated to assess scanner performance, stability, comparability and assess the accuracy of quantitative relaxation time imaging. The phantom is unique in having traceability to the International System of Units, a high level of precision, and monitoring by a national metrology institute. Here, we describe the phantom design, construction, imaging protocols, and measurement of geometric distortion, resolution, slice profile, signal‐to‐noise ratio (SNR), proton‐spin relaxation times, image uniformity and proton density. Methods The system phantom, designed by the International Society of Magnetic Resonance in Medicine ad hoc committee on Standards for Quantitative MR, is a 200 mm spherical structure that contains a 57‐element fiducial array; two relaxation time arrays; a proton density/SNR array; resolution and slice‐profile insets. Standard imaging protocols are presented, which provide rapid assessment of geometric distortion, image uniformity, T 1 and T 2 mapping, image resolution, slice profile, and SNR. Results Fiducial array analysis gives assessment of intrinsic geometric distortions, which can vary considerably between scanners and correction techniques. This analysis also measures scanner/coil image uniformity, spatial calibration accuracy, and local volume distortion. An advanced resolution analysis gives both scanner and protocol contributions. SNR analysis gives both temporal and spatial contributions. Conclusions A standard system phantom is useful for characterization of scanner performance, monitoring a scanner over time, and to compare different scanners. This type of calibration structure is useful for quality assurance, benchmarking quantitative MRI protocols, and to transition MRI from a qualitative imaging technique to a precise metrology with documented accuracy and uncertainty.
Race, Income, and Survival in Stage III Colon Cancer: CALGB 89803 (Alliance)
Lee, Seohyuk , Zhang, Sui , Ou, Fang‐Shu , Wolfe, Eric, Ogino, Shuji , Niedzwiecki, Donna , Mowat, Rex B., Whittom, Renaud , Hantel, Alexander, Benson, Al B. , Atienza, Daniel, Messino, Michael J., Kindler, Hedy L. , Gross, Cary P. , Irwin, Melinda L. , Meyerhardt, Jeffrey A. , Fuchs, Charles S. , Ou, Fang-Shu , Wolfe, Eric G, Ogino, Shuji , Kindler, Hedy , Venook, Alan P , Fuchs, Charles S , Meyerhardt, Jeffrey A , Niedzwiecki, Donna , Ma, Chao , Saltz, Leonard B. , Mayer, Robert J. , Venook, Alan P.

Mayo Clinic

JNCI Cancer Spectrum | April 11, 2021 | Volume: 5 | Issue: 3 | Pages: No page available

10.1093/jncics/pkab034 | PMID 34104867 Get It

Abstract Background Disparities in colon cancer outcomes have been reported across race and socioeconomic status, which may reflect, in part, access to care. We sought to assess the influences of race and median household income (MHI) on outcomes among colon cancer patients with similar access to care. Methods We conducted a prospective, observational study of 1206 stage III colon cancer patients enrolled in the CALGB 89803 randomized adjuvant chemotherapy trial. Race was self-reported by 1116 White and 90 Black patients at study enrollment; MHI was determined by matching 973 patients’ home zip codes with publicly available US Census 2000 data. Multivariate analyses were adjusted for baseline sociodemographic, clinical, dietary, and lifestyle factors. All statistical tests were 2-sided. Results Over a median follow-up of 7.7 years, the adjusted hazard ratios for Blacks (compared with Whites) were 0.94 (95% confidence interval [CI] = 0.66 to 1.35, P = .75) for disease-free survival, 0.91 (95% CI = 0.62 to 1.35, P = .65) for recurrence-free survival, and 1.07 (95% CI = 0.73 to 1.57, P = .73) for overall survival. Relative to patients in the highest MHI quartile, the adjusted hazard ratios for patients in the lowest quartile were 0.90 (95% CI = 0.67 to 1.19, Ptrend = .18) for disease-free survival, 0.89 (95% CI = 0.66 to 1.22, Ptrend = .14) for recurrence-free survival, and 0.87 (95% CI = 0.63 to 1.19, Ptrend = .23) for overall survival. Conclusions In this study of patients with similar health-care access, no statistically significant differences in outcomes were found by race or MHI. The substantial gaps in outcomes previously observed by race and MHI may not be rooted in differences in tumor biology but rather in access to quality care.
Medical Malpractice and Vestibular Schwannomas: A Nationwide Review
Boyke, Andre E. , Sethi, Atharv, Funari, Abigail , Agarwal, Vijay , Bader, Edward R. , Alvi, Mohammed Ali

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | April 8, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0041-1725396 Get It

Stereotactic Radiosurgery (SRS) with or without Surgical Resection for Pituitary Adenoma: Insights from the National Cancer Database
Boyke, Andre E. , Naidu, Ishan , Funari, Abigail , Sethi, Atharv, Agarwal, Vijay , Alvi, Mohammed Ali , Bader, Edward R.

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | April 8, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0041-1725388 Get It

Temporal Trends, Regional Analysis, and Characteristics of Utilization of Stereotactic Radiosurgery for Pituitary Tumors in the United States: Analyses from the National Cancer Database
Boyke, Andre E. , Naidu, Ishan , Funari, Abigail , Sethi, Atharv, Agarwal, Vijay , Alvi, Mohammed Ali , Bader, Edward R.

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | April 8, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0041-1725385 Get It

Delivering Equitable Care to Underserved Neuro-oncology Populations
Porter, Alyx B. , Chukwueke, Ugonma , Mammoser, Aaron, Friday, Bret Edward Buckley, Hervey‐Jumper, Shawn L.

Mayo Clinic

American Society of Clinical Oncology Educational Book | April 8, 2021 | Volume: No volume available | Issue: 41 | Pages: 38-46

10.1200/edbk_320803 | PMID 33830829 Get It

It is widely recognized that subspecialized multidisciplinary care improves neuro-oncology outcomes. Optimizing patient outcomes relies on the expertise of the treating physicians, neuroradiology and neuropathology, and supportive services familiar with common neurologic syndromes that occur after brain tumor diagnosis and treatment. Despite an increasing number of providers, patient access to specialized multidisciplinary care and clinical trials remains limited. Barriers to equitable health care exist across the United States, with marginalized communities being impacted disproportionately. Such disparity causes increased morbidity and mortality for patients from backgrounds with various elements of diversity. Limited attention to this inequity has resulted in an incomplete understanding of the spectrum of experiences that patients with neuro-oncologic diseases encounter. Clinical trials represent the highest standard and quality of care in medicine, but inclusion of under-represented and underserved groups consistently lags behind counterpart participants from majority racial and ethnic groups. Through provider education as it pertains to issues from bias and health literacy to increasing clinical trial enrollment and offering opportunities through telemedicine, opportunities for improving access to high-quality neuro-oncologic care are explored.
Single incision endoscopic strip craniectomy for sagittal craniosynostosis
Ahn, Edward S. , Bhandarkar, Archis R.

Mayo Clinic

Neurosurgical Focus: Video | April 6, 2021 | Volume: 4 | Issue: 2 | Pages: V10

10.3171/2021.1.focvid20120 | PMID 36284855 Get It

The authors describe an endoscopic strip craniectomy through a single incision for the treatment of sagittal craniosynostosis in a young infant. The endoscopic strip craniectomy was first introduced with the use of two incisions on either end of the fused suture. This single-incision technique offers several advantages. There is a cosmetic advantage and a reduced risk of wound complications. This technique also allows for early control of emissary veins and an inside-out identification of the lambdoid sutures. Endoscopic visualization is optimized to reduce the risk of blood loss, especially because circulating blood volume is very limited in these young infants. The video can be found here: https://vimeo.com/514366415